An optimized peptide vaccine strategy capable of inducing multivalent CD8+ T cell responses with potent antitumor effects

Hyun Il Cho, Soo Hyun Jung, Hyun Jung Sohn, Esteban Celis, Tai Gyu Kim

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Therapeutic cancer vaccines are an attractive alternative to conventional therapies for treating malignant tumors, and successful tumor eradication depends primarily on obtaining high numbers of long-lasting tumor-reactive CD8+ T cells. Dendritic cell (DC)-based vaccines constitute a promising approach for treating cancer, but in most instances low immune responses and suboptimal therapeutic effects are achieved indicating that further optimization is required. We describe here a novel vaccination strategy with peptide-loaded DCs followed by a mixture of synthetic peptides, polyinosine-polycytidylic acid (poly-IC) and anti-CD40 antibodies (TriVax) for improving the immunogenicity and therapeutic efficacy of DC-based vaccines in a melanoma mouse model. TriVax immunization 7–12 d after priming with antigen-loaded DCs generated large numbers of long-lasting multiple antigen-specific CD8+ T cells capable of recognizing tumor cells. These responses were far superior to those generated by homologous immunizations with either TriVax or DCs. CD8+ T cells but not CD4+ T cells or NK cells mediated the therapeutic efficacy of this heterologous prime-boost strategy. Moreover, combinations of this vaccination regimen with programmed cell death-1 (PD-1) blockade or IL2 anti-IL2 antibody complexes led to complete disease eradication and survival enhancement in melanoma-bearing mice. The overall results suggest that similar strategies would be applicable for the design of effective therapeutic vaccination for treating viral diseases and various cancers, which may circumvent current limitations of cell-based cancer vaccines.

Original languageEnglish (US)
JournalOncoImmunology
Volume4
Issue number11
DOIs
StatePublished - Nov 2 2015

Fingerprint

Subunit Vaccines
T-Lymphocytes
Neoplasms
Cancer Vaccines
Vaccination
Dendritic Cells
Interleukin-2
Anti-Idiotypic Antibodies
Melanoma
Immunization
Vaccines
Disease Eradication
CD8 Antigens
Poly C
Therapeutics
Peptides
Therapeutic Uses
Virus Diseases
Natural Killer Cells
Cell Death

Keywords

  • cancer vaccine
  • dendritic cells
  • heterologous prime-boost vaccination
  • multivalent CD8 T cells
  • peptide-based vaccine
  • tumor immunity

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

An optimized peptide vaccine strategy capable of inducing multivalent CD8+ T cell responses with potent antitumor effects. / Cho, Hyun Il; Jung, Soo Hyun; Sohn, Hyun Jung; Celis, Esteban; Kim, Tai Gyu.

In: OncoImmunology, Vol. 4, No. 11, 02.11.2015.

Research output: Contribution to journalArticle

@article{ef5e18a7188f4c0f8c2c1bca9c26a378,
title = "An optimized peptide vaccine strategy capable of inducing multivalent CD8+ T cell responses with potent antitumor effects",
abstract = "Therapeutic cancer vaccines are an attractive alternative to conventional therapies for treating malignant tumors, and successful tumor eradication depends primarily on obtaining high numbers of long-lasting tumor-reactive CD8+ T cells. Dendritic cell (DC)-based vaccines constitute a promising approach for treating cancer, but in most instances low immune responses and suboptimal therapeutic effects are achieved indicating that further optimization is required. We describe here a novel vaccination strategy with peptide-loaded DCs followed by a mixture of synthetic peptides, polyinosine-polycytidylic acid (poly-IC) and anti-CD40 antibodies (TriVax) for improving the immunogenicity and therapeutic efficacy of DC-based vaccines in a melanoma mouse model. TriVax immunization 7–12 d after priming with antigen-loaded DCs generated large numbers of long-lasting multiple antigen-specific CD8+ T cells capable of recognizing tumor cells. These responses were far superior to those generated by homologous immunizations with either TriVax or DCs. CD8+ T cells but not CD4+ T cells or NK cells mediated the therapeutic efficacy of this heterologous prime-boost strategy. Moreover, combinations of this vaccination regimen with programmed cell death-1 (PD-1) blockade or IL2 anti-IL2 antibody complexes led to complete disease eradication and survival enhancement in melanoma-bearing mice. The overall results suggest that similar strategies would be applicable for the design of effective therapeutic vaccination for treating viral diseases and various cancers, which may circumvent current limitations of cell-based cancer vaccines.",
keywords = "cancer vaccine, dendritic cells, heterologous prime-boost vaccination, multivalent CD8 T cells, peptide-based vaccine, tumor immunity",
author = "Cho, {Hyun Il} and Jung, {Soo Hyun} and Sohn, {Hyun Jung} and Esteban Celis and Kim, {Tai Gyu}",
year = "2015",
month = "11",
day = "2",
doi = "10.1080/2162402X.2015.1043504",
language = "English (US)",
volume = "4",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "11",

}

TY - JOUR

T1 - An optimized peptide vaccine strategy capable of inducing multivalent CD8+ T cell responses with potent antitumor effects

AU - Cho, Hyun Il

AU - Jung, Soo Hyun

AU - Sohn, Hyun Jung

AU - Celis, Esteban

AU - Kim, Tai Gyu

PY - 2015/11/2

Y1 - 2015/11/2

N2 - Therapeutic cancer vaccines are an attractive alternative to conventional therapies for treating malignant tumors, and successful tumor eradication depends primarily on obtaining high numbers of long-lasting tumor-reactive CD8+ T cells. Dendritic cell (DC)-based vaccines constitute a promising approach for treating cancer, but in most instances low immune responses and suboptimal therapeutic effects are achieved indicating that further optimization is required. We describe here a novel vaccination strategy with peptide-loaded DCs followed by a mixture of synthetic peptides, polyinosine-polycytidylic acid (poly-IC) and anti-CD40 antibodies (TriVax) for improving the immunogenicity and therapeutic efficacy of DC-based vaccines in a melanoma mouse model. TriVax immunization 7–12 d after priming with antigen-loaded DCs generated large numbers of long-lasting multiple antigen-specific CD8+ T cells capable of recognizing tumor cells. These responses were far superior to those generated by homologous immunizations with either TriVax or DCs. CD8+ T cells but not CD4+ T cells or NK cells mediated the therapeutic efficacy of this heterologous prime-boost strategy. Moreover, combinations of this vaccination regimen with programmed cell death-1 (PD-1) blockade or IL2 anti-IL2 antibody complexes led to complete disease eradication and survival enhancement in melanoma-bearing mice. The overall results suggest that similar strategies would be applicable for the design of effective therapeutic vaccination for treating viral diseases and various cancers, which may circumvent current limitations of cell-based cancer vaccines.

AB - Therapeutic cancer vaccines are an attractive alternative to conventional therapies for treating malignant tumors, and successful tumor eradication depends primarily on obtaining high numbers of long-lasting tumor-reactive CD8+ T cells. Dendritic cell (DC)-based vaccines constitute a promising approach for treating cancer, but in most instances low immune responses and suboptimal therapeutic effects are achieved indicating that further optimization is required. We describe here a novel vaccination strategy with peptide-loaded DCs followed by a mixture of synthetic peptides, polyinosine-polycytidylic acid (poly-IC) and anti-CD40 antibodies (TriVax) for improving the immunogenicity and therapeutic efficacy of DC-based vaccines in a melanoma mouse model. TriVax immunization 7–12 d after priming with antigen-loaded DCs generated large numbers of long-lasting multiple antigen-specific CD8+ T cells capable of recognizing tumor cells. These responses were far superior to those generated by homologous immunizations with either TriVax or DCs. CD8+ T cells but not CD4+ T cells or NK cells mediated the therapeutic efficacy of this heterologous prime-boost strategy. Moreover, combinations of this vaccination regimen with programmed cell death-1 (PD-1) blockade or IL2 anti-IL2 antibody complexes led to complete disease eradication and survival enhancement in melanoma-bearing mice. The overall results suggest that similar strategies would be applicable for the design of effective therapeutic vaccination for treating viral diseases and various cancers, which may circumvent current limitations of cell-based cancer vaccines.

KW - cancer vaccine

KW - dendritic cells

KW - heterologous prime-boost vaccination

KW - multivalent CD8 T cells

KW - peptide-based vaccine

KW - tumor immunity

UR - http://www.scopus.com/inward/record.url?scp=84941774508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941774508&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2015.1043504

DO - 10.1080/2162402X.2015.1043504

M3 - Article

AN - SCOPUS:84941774508

VL - 4

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 11

ER -